- Product
- Will Kypris become dominant in multiple myeloma markets?
- by Whang, byung-woo May 10, 2021 05:56am
- "New treatments will also emerge in the treatment of myeloma. However, its importance is still expected to continue when Kypris compares combined therapy features with a single formulation and other formulations." As multiple myeloma is difficult to completely heal and many recurrences occur, recurrence and non-responsive polymyeloma is consider
- Product
- Pharmacists & employees in their 20s receive Pfizer vaccine
- by May 7, 2021 06:01am
- Pharmacists and employees under the age of 30 who were excluded from the AZ vaccination are expected to receive the Pfizer vaccine next month. The KCDA announced on the 4th that the Pfizer vaccine for social essential personnel and military soldiers under the age of 30 who have been suspended from vaccinating AZ vaccine due to "thrombotic sid
- Product
- The price of Rotarix has also increased
- by Moon, sung-ho Apr 30, 2021 06:09am
- As prices have increased for cervical cancer vaccines and rotavirus vaccines that prevent neonatal enteritis, the burden on hospitals and clinics is increasing. Some medical organizations are raising the issue of unilateral price hikes for global pharmaceutical companies, but there is currently no clear solution. The medical staff who have
- Product
- Why are pharmacists in the AZ vaccination relay?
- by Apr 22, 2021 05:53am
- On social media, pharmacists' vaccination application reservation verification shots appeared in a row. "I made an appointment for vaccination", "I applied for it too" Since yesterday (19th), a vaccine application for pharmacies through the KCDA website has been in progress, and pharmacists who have completed reservations are sharing informa
- Product
- Korean bio-pharma companies attract attention at AACR 2021
- by Whang, byung-woo Apr 21, 2021 05:49am
- The AACR 2021 Annual Meeting, the largest meeting on cancer research in the world, took place from April 10th to April 15th. At the meeting, new combination therapies were introduced, raising expectations for the use of new mechanisms of action in the field of cancer treatment. Through a presentation of data on the use of nivolumab (Opdivo) i
- Product
- Korean-made new drug Rolontis readies for FN drug market
- by Moon, sung-ho Mar 24, 2021 05:45am
- Hanmi Pharmaceutical is readying for the febrile neutropenia (FN) treatment market for its first bio new drug Rolontis (eflapegrastim), as it finally received the South Korean health authority’s market authorization. This could be an opportunity for the South Korean company to take over the domestic drug market, currently led by global phar
- Product
- This situation of mixing Lyrica with other doses is absurd
- by Kang, Shin-Kook Mar 22, 2021 06:16am
- When it was confirmed that Pfizer Korea's Lyrica had mixed drugs with different doses, The Korean Pharmaceutical Association urged a countermeasure to prevent recurrence. The KPA(Chairman Dae-eop Kim) made a statement on the 17th, saying, "The case where different doses of pharmaceuticals are mixed & packaging in the bottle is a serious prob
- Product
- KMA recommends Tylenol for fever after AZ vaccination
- by Kang, Shin-Kook Mar 10, 2021 06:26am
- After the AstraZeneca COVID-19 vaccination, the frequency of fever or muscle pain was found to be 20-30%, and the KMA recommended taking Tylenol. The KMA (Chairman Choi Daejip) released a recommendation containing countermeasures after the COVID-19 vaccine vaccination to the public on the 6th. The KMA said, "In the case of the AstraZenec
- Product
- Frequently consumed OTC drug prices differ in pharmacies
- by Kang, Shin-Kook Feb 3, 2021 06:09am
- The price gap of Tyrenol ER, Gelfos and Tak-Sen widened up to 150 percent among different pharmacies selling the drugs, which contrasted against high-priced bundle-packaged drugs showing barely any gap. Daily Pharm surveyed 22 pharmacies in Incheon for their frequently sold over-the-counter (OTC) drug retail prices as of February, and it fou
- Product
- Efficacy vs. More inoculation? Vaccination plan in dilemma
- by Choi-sun Jan 22, 2021 06:26am
- The public is questioning the actual efficacy of the alternative regimen of the COVID-19 vaccine that reduces dose or delays the booster dose due to the vaccine shortage, Relevant experts give conflicted opinions. Some argue the government should maximize the efficacy with the limited resource, whereas some claim medical evidence is integral
